Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Critical reviews in oncology/hematology

• Publication date

  2014-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.critrevonc.2014.05.008PMID 24952997
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.

  2014cited by this paper
• Small cell carcinoma of the prostate

  2014cited by this paper
• MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms

  2013cited by this paper
• Treatment with the Radiolabelled Somatostatin Analog 177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

  2013cited by this paper
• Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.

  2013cited by this paper
• Randomized phase II study of danusertib in patients with metastatic castration‐resistant prostate cancer after docetaxel failure

  2013cited by this paper
• Zoledronic acid but not somatostatin analogs exerts anti‐tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration‐resistant prostate cancer

  2013cited by this paper
• Anterior gradient 2 (AGR2): Blood‐based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype

  2013cited by this paper
• Circulating tumor cells: utopia or reality?

  2013cited by this paper
• Human ASH‐1 Promotes Neuroendocrine Differentiation in Androgen Deprivation Conditions and Interferes With Androgen Responsiveness in Prostate Cancer Cells

  2013cited by this paper
• Propagation of Human Prostate Cancer Stem-Like Cells Occurs through EGFR-Mediated ERK Activation

  2013cited by this paper
• Constitutively Active Androgen Receptor Variants Upregulate Expression of Mesenchymal Markers in Prostate Cancer Cells

  2013cited by this paper
• Human Prostate Side Population Cells Demonstrate Stem Cell Properties in Recombination with Urogenital Sinus Mesenchyme

  2013cited by this paper
• Molecular and Cellular Pathobiology Interleukin-1 b Promotes Skeletal Colonization and Progression of Metastatic Prostate Cancer Cells with Neuroendocrine Features

  2013cited by this paper
• The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing.

  2013cited by this paper
• Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

  2013cited by this paper
• The role of Snail in prostate cancer

  2012cited by this paper
• Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.

  2012cited by this paper
• EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway.

  2012cited by this paper
• Stem‐Like Cells with Luminal Progenitor Phenotype Survive Castration in Human Prostate Cancer

  2012cited by this paper
• Cell-to-Cell Signaling Influences the Fate of Prostate Cancer Stem Cells and Their Potential to Generate More Aggressive Tumors

  2012cited by this paper
• Prostate cancer stem cells.

  2012cited by this paper
• MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2

  2012cited by this paper
• Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.

  2012cited by this paper
• Epithelial immune cell-like transition (EIT): a proposed transdifferentiation process underlying immune-suppressive activity of epithelial cancers.

  2012cited by this paper
• Perspectives on mTOR inhibitors for castration-refractory prostate cancer.

  2012cited by this paper
• Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle?

  2011cited by this paper
• Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2.

  2011cited by this paper
• Neuroendocrine tumor cells in prostate cancer: Evaluation of the neurosecretory products serotonin, bombesin, and gastrin – impact on angiogenesis and clinical follow‐up

  2011cited by this paper
• Recent clinical trials of mTOR-targeted cancer therapies.

  2011cited by this paper
• Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.

  2011cited by this paper
• Prognostic significance of neuroendocrine differentiation in patients with Gleason score 8-10 prostate cancer treated with primary radiotherapy.

  2011cited by this paper
• Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.

  2011cited by this paper
• Molecular characterization of neuroendocrine prostate cancer (NEPC) and identification of new drug targets.

  2011cited by this paper
• Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors.

  2010cited by this paper
• Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells

  2010cited by this paper
• Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis.

  2010cited by this paper
• Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells

  2010cited by this paper
• Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells.

  2010cited by this paper
• Dramatically elevated circulating tumor cell numbers in a patient with small cell neuroendocrine carcinoma of the prostate.

  2010cited by this paper
• Oct4A is expressed by a subpopulation of prostate neuroendocrine cells

  2009cited by this paper
• Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer

  2009cited by this paper
• Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC)

  2009cited by this paper
• Neuroendocrine differentiation in prostate cancer.

  2009cited by this paper
• Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.

  2009cited by this paper
• Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology

  2009cited by this paper
• Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer

  2009cited by this paper
• Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.

  2009cited by this paper
• A luminal epithelial stem cell that is a cell of origin for prostate cancer

  2009cited by this paper
• Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC).

  2009cited by this paper
• Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

  2008cited by this paper
• The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells.

  2008cited by this paper
• Pasireotide (SOM230): development, mechanism of action and potential applications.

  2008cited by this paper
• The epithelial-mesenchymal transition generates cells with properties of stem cells.

  2008cited by this paper
• Human ASH1 expression in prostate cancer with neuroendocrine differentiation

  2008cited by this paper
• The combination of docetaxel and the somatostatin analogue lanreotide on androgen‐independent docetaxel‐resistant prostate cancer: experimental data

  2008cited by this paper
• Clinical implications of neuroendocrine differentiation in prostate cancer

  2007cited by this paper
• Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

  2007cited by this paper
• Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease.

  2007cited by this paper
• Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers.

  2007cited by this paper
• Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.

  2007cited by this paper
• Combination of somatostatin analogues and dexamethasone (antisurvival‐factor concept) with luteinizing hormone‐releasing hormone in androgen ablation‐refractory prostate cancer with bone metastasis

  2007cited by this paper
• Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy

  2007cited by this paper
• Cancer stem cells.

  2006cited by this paper
• Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway Is Essential for Neuroendocrine Differentiation of Prostate Cancer*

  2006cited by this paper
• Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach

  2006cited by this paper
• Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells.

  2006cited by this paper
• The grey zone between pure (neuro)endocrine and non-(neuro)endocrine tumours: a comment on concepts and classification of mixed exocrine–endocrine neoplasms

  2006cited by this paper
• Immunohistochemical characterization of neuroendocrine cells in prostate cancer

  2006cited by this paper
• Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.

  2006cited by this paper
• Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer

  2006cited by this paper
• Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.

  2005cited by this paper
• Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling.

  2005cited by this paper
• Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer.

  2005cited by this paper
• Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer.

  2005cited by this paper
• Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.

  2005cited by this paper
• Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma.

  2005cited by this paper
• CD133, a novel marker for human prostatic epithelial stem cells

  2004cited by this paper
• Evidence of pluripotent human prostate stem cells in a human prostate primary xenograft model

  2004cited by this paper
• Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study.

  2004cited by this paper
• Role of 99mTc-Bombesin Scan in Diagnosis and Staging of Prostate Cancer

  2004cited by this paper
• Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma.

  2004cited by this paper
• Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines

  2004cited by this paper
• Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK

  2004cited by this paper
• Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer.

  2004cited by this paper
• Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma

  2003cited by this paper
• Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer.

  2003cited by this paper
• Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma

  2002cited by this paper
• Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.

  2002cited by this paper
• Different profiles of neuroendocrine cell differentiation evolve in the PC‐310 human prostate cancer model during long‐term androgen deprivation

  2002cited by this paper
• Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer

  2002cited by this paper
• Neuroendocrine cells in human prostate over‐express the anti‐apoptosis protein survivin

  2001cited by this paper
• Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin‐A, prostate‐specific antigen, and insulin‐like growth factor‐1 in advanced prostate cancer patients

  2001cited by this paper
• Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments.

  2001cited by this paper
• Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.

  2001cited by this paper
• Potential clinical value of circulating chromogranin A in patients with prostate carcinoma.

  2001cited by this paper
• Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status.

  2001cited by this paper
• Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.

  2000cited by this paper
• STAT3 mediates IL‐6‐induced neuroendocrine differentiation in prostate cancer cells

  2000cited by this paper
• Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment

  2000cited by this paper

• The role of neuroendocrine differentiation in treatment resistance of prostate cancer and intervention strategies

  2026cites this paper
• Survival outcomes and prognostic factors of gastric carcinoma with neuroendocrine differentiation

  2026cites this paper
• LncRNA PCAT6 promotes progression and metastasis of colonic neuroendocrine carcinoma via MAPK pathway

  2025cites this paper
• Koningic acid reduces tumor activity in neuroendocrine prostate cancer by inhibiting glycolysis.

  2025cites this paper
• Environmental interpretation of the impact of vehicle emissions on prostate cancer progression

  2025cites this paper
• Widespread activation and critical role of EMT and stemness in the neuroendocrine differentiation of prostate cancer (Review)

  2025cites this paper
• Identification and Initial Validation of Neuroendocrine Differentiation as a Novel Prognostic Factor in Stage II Colorectal Cancer Patients

  2024cites this paper
• Characterization of Epithelial–Mesenchymal and Neuroendocrine Differentiation States in Pancreatic and Small Cell Ovarian Tumor Cells and Their Modulation by TGF-β1 and BMP-7

  2024cites this paper
• Proteomic Analysis of Microsomal Proteins Reveals That MVP Is Crucial for the Secretion of GDF-15, Which in Turn Promotes the Neuroendocrine Differentiation of PCa Cells.

  2024cites this paper
• GD2 and its biosynthetic enzyme GD3 synthase promote tumorigenesis in prostate cancer by regulating cancer stem cell behavior

  2024cites this paper
• GD2 and its biosynthetic enzyme GD3 synthase promote tumorigenesis in prostate cancer by regulating cancer stem cell behavior

  2023cites this paper
• Single-cell analysis of castration-resistant prostate cancers to identify potential biomarkers for diagnosis and prognosis of neuroendocrine prostate cancer.

  2023cites this paper
• A novel GRK3-HDAC2 regulatory pathway is a key direct link between neuroendocrine differentiation and angiogenesis in prostate cancer progression.

  2023cites this paper
• Autonomous action and cooperativity between the ONECUT2 transcription factor and its 3′ untranslated region

  2023cites this paper
• PRMT5 promotes chemotherapy‐induced neuroendocrine differentiation in NSCLC

  2023cites this paper
• JNJ-64619178 radiosensitizes and suppresses fractionated ionizing radiation-induced neuroendocrine differentiation (NED) in prostate cancer

  2023cites this paper
• The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC

  2022cites this paper
• Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease

  2022cites this paper
• Proteomic and Transcriptomic Profiling Reveals Mitochondrial Oxidative Phosphorylation as Therapeutic Vulnerability in Androgen Receptor Pathway Active Prostate Tumors

  2022cites this paper
• Targeting protein arginine methyltransferase 5 (PRMT5) suppresses radiation-induced neuroendocrine differentiation and sensitizes prostate cancer cells to radiation.

  2022cites this paper
• An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA

  2021cites this paper
• N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells

  2021cites this paper
• Validation of SV2A-Targeted PET Imaging for Noninvasive Assessment of Neuroendocrine Differentiation in Prostate Cancer

  2021cites this paper
• Blocking GRP/GRP-R signaling decreases expression of androgen receptor splice variants and inhibits tumor growth in castration-resistant prostate cancer

  2021cites this paper
• Effect of abiraterone combined with prednisone on serum CgA and NSE in metastatic castration-resistant prostate cancer without previous chemotherapy

  2021cites this paper
• Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine

  2021influential citation
• Depression accelerates gastric cancer invasion and metastasis by inducing a neuroendocrine phenotype via the catecholamine/β2‐AR/MACC1 axis

  2021cites this paper
• Prostate Cancer With Neuroendocrine Differentiation Recurring After Treatment With 177Lu-PSMA: A Chance for 177Lu-DOTATATE Therapy?

  2021cites this paper
• Comprehensive analysis of serum chromogranin A and neuron‐specific enolase levels in localized and castration‐resistant prostate cancer

  2020cites this paper
• New Immunotherapy Biomarker N-Cadherin Rescue Immunosuppress Caused by PD-L1/IDO-1 in Prostate Cancer

  2020cites this paper
• Isolation and Characterization of Two Novel Colorectal Cancer Cell Lines, Containing a Subpopulation with Potential Stem-Like Properties: Treatment Options by MYC/NMYC Inhibition

  2020cites this paper
• Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression

  2020cites this paper
• Plasma Androgen Receptor in Prostate Cancer

  2019cites this paper
• Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.

  2019cites this paper
• The Landscape of Circular RNA in Cancer.

  2019cites this paper
• Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors

  2019cites this paper
• mTOR PRAS 40 Deptor GβL Raptor mTORC 1 Protor mTOR mSIN 1 Deptor GβL Rictor

  2019cites this paper
• CMAR_A_190678 2747..2758

  2019cites this paper
• Evaluation of CisBio ELISA for Chromogranin A Measurement.

  2019cites this paper
• Development of chimeric and bifunctional antagonists for CLR/RAMP receptors

  2019cites this paper
• Inflammation: predictive factor for negative evolution of prostate diseases.

  2019cites this paper
• Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists

  2019cites this paper
• New-onset resistant hypertension in a newly diagnosed prostate cancer patient.

  2019cites this paper
• Response prediction of 177Lu-PSMA-617 RLT using PSA, Chromogranin A, and LDH

  2019cites this paper
• Response Prediction of 177Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase

  2019cites this paper
• Chromogranin A is a predictor of prognosis in patients with prostate cancer: a systematic review and meta-analysis

  2019cites this paper
• Testosterone levels and androgen receptor copy number variations in castration‐resistant prostate cancer treated with abiraterone or enzalutamide

  2019cites this paper
• Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.

  2018cites this paper
• Interleukin‐6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation

  2018influential citation
• Association among metabolic syndrome, inflammation, and survival in prostate cancer.

  2018cites this paper
• 68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer

  2018cites this paper
• CXCL12γ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes.

  2018influential citation
• PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis

  2018cites this paper
• Prognostic role of chromogranin A in castration-resistant prostate cancer: a meta-analysis

  2018cites this paper
• [Infiltrating mast cells promote neuroendocrine differentiation and increase docetaxel resistance of prostate cancer cells by up-regulating p21].

  2018cites this paper
• Reduction of two histone marks, H3k9me3 and H3k27me3 by epidrug induces neuroendocrine differentiation in prostate cancer

  2018cites this paper
• Serum Chromogranin-A based Prognosis In Metastatic Castration Resistant Prostate Cancer

  2018cites this paper
• Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis

  2018cites this paper
• Plasma androgen receptor and serum chromogranin A in advanced prostate cancer

  2018cites this paper
• Recent Advances in Prostate Cancer Treatment and Drug Discovery

  2018cites this paper
• Chromogranin A as a valid marker in oncology: Clinical application or false hopes?

  2017cites this paper
• Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer

  2017cites this paper
• MAOA-a novel decision maker of apoptosis and autophagy in hormone refractory neuroendocrine prostate cancer cells

  2017cites this paper
• Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer

  2017cites this paper
• Targeting Phenotypic Plasticity in Prostate Cancer

  2017cites this paper
• Induction of neuroendocrine differentiation in castration resistant prostate cancer cells by adipocyte differentiation-related protein (ADRP) delivered by exosomes.

  2017influential citation
• Immunotherapy for Prostate Cancer: Where We Are Headed

  2017cites this paper
• Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis

  2017cites this paper
• Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy‐naive metastatic castration‐resistant prostate cancer

  2017cites this paper
• [Management of neuroendocrine prostate carcinoma: Literature review].

  2016cites this paper
• Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone

  2016cites this paper
• MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity

  2016cites this paper
• Intracellular Elemental Patterns of Apoptosis Resistance in Transdifferentiated Androgen-Dependent Prostatic Carcinoma Cells

  2016cites this paper
• GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells

  2016cites this paper
• Emerging mutations and functional changes of androgen receptor associated with treatment resistance in prostate cancer

  2016cites this paper
• NOVEL MECHANISMS OF β-ADRENERGIC SIGNALING IN PROSTATE CANCER PROGRESSION

  2016cites this paper
• Neuroendocrine-like cells -derived CXCL10 and CXCL11 induce the infiltration of tumor-associated macrophage leading to the poor prognosis of colorectal cancer

  2016cites this paper
• Small Cell Carcinoma of Prostate: A Case Report of a Patient With a Normal PSA and a Giant Prostate Volume

  2016cites this paper
• Small-cell neuroendocrine cancer of the prostate: an atypical presentation of a common disease

  2016cites this paper
• Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview

  2016cites this paper
• Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer

  2016cites this paper
• REST reduction is essential for hypoxia-induced neuroendocrine differentiation of prostate cancer cells by activating autophagy signaling

  2016cites this paper
• NTS/NTR1 co-expression enhances epithelial-to-mesenchymal transition and promotes tumor metastasis by activating the Wnt/β-catenin signaling pathway in hepatocellular carcinoma

  2016cites this paper
• Hormone resistance and neuroendocrine differentiation due to accumulation of genetic lesions during clonal evolution of prostate cancer

  2016cites this paper
• GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs.

  2015cites this paper
• β-Adrenergic Receptor Signaling in Prostate Cancer

  2015cites this paper
• Neuroendocrine Differentiation in Prostate Cancer: A Mechanism of Radioresistance and Treatment Failure

  2015cites this paper
• Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer.

  2015cites this paper
• Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.

  2015cites this paper
• An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients

  2015cites this paper
• Capsaicin as a Novel Chemopreventive and Therapeutic Option for Prostate Cancer

  2015cites this paper
• Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.

  2014cites this paper
• Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone

  2014cites this paper
• Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide

  2014cites this paper